Skip to main content
NemesanszkyElemer_Intrahepatikus

 

Irodalom:
1. Guicciardi ME., Gores GJ.: Cholestatic hepatocellular injury: what do we know and how shoud we
proceed. J. Hepatology 2006, 42, 297-300.
2. Fickert P et al.: Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in MDR
knockout mice. Gastroenterology, 2004, 127, 261-274.
3. Inagaki T. et al.: Regulation of antibacterial defense int he small intestine by the nuclear bile acid receptor.
Proc. Natl. Acad. Sci, 2006, 103, 390-3925.
4. Marschall HU. et al.: Complementary stimulation of hepatobiliary transport and detoxification system
by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2006, 129, 476-485
5. Tiribelli C., Ostrow JD.: Intestinal flora and bilirubin. J. Hepatology, 2006, 42, 170-172.
6. Paumgartner G.: Medical treatment of cholestatic liver diseases. Word J. Gastroenterol. 2006, 12,
4445-4451.
7. Rutherford AE., Pratt DS.: Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 2006, 22,
209-214.
8. Pauli-Magnus C., Meier PJ.: Hepatobiliary transporters and drug-induced cholestasis. Hepatology,
2006, 44, 778-787.
9. Borst P., Zelner N., Wetering K.: MRP2 and 3 in heath and disease. CancerLetters 2006, 234, 51-61.
10. Ellis E. et al.: Successful treatment of severe unconjugated hyperlbilirbinaemia via induction of
UGT1A1 by rifampicin. J. Hepatology, 2006, 44, 243-245.
11. Bergasa NV.: The pruritus of cholestasis. J. Hepatology 2006, 43, 1078-1088.
12. Bergasa NV.: Medical palliation of the jaundiced patient with prutitus. J. Hepatology 2006, 35, 113-123.
13. Stapekbroek JM. et al.: Nasobiliary drainage induced long-lasting remission in benign reccurent intrahepatic
cholestasis. Hepatology 2006, 43, 51-53.
14. Beuers U.: Mechanism and sites of action of ursodeoxycholic acid in cholestasis. Clin. Practice
Gastroenterol. Hepatol. 2006, 3, 318-328.
15. Pagán B. et al.: Budesonid combined with ursodeoxycholic acid in primary biliary cirrhosis with
advanced liver damage. Internal Medicine 2006, 17, 508-510.
16. Gluud C., Christensen E.: Ursodeoxycholic acid for primary biliary cirrhosis EMB Reviews-Cochrane
Darabase 2006, 4, 136.
17. Sorokin A. et al.: Primary biliary cirrhosis, hyperlipidaemia, and atherosclerotic risk Atherosclerosis
2006, 12, 122-126.
18. Blach DD.: Chronic cholestasis and dyslipidaemia: what is the cardiocûvascular risk? J. Pediatrics
2006, 146, 306-307.
19. MacFaul GR., Chapman RW.: Sclerosisg cholangitis. Curr. Opinion Gastroenterol. 2006, 22, 288-293.
21. Jonas E. et al.: Mesurement of parenchymal function and bile duct flow in primary sclerosisng cholangitis
using dynamic 99mTc-HIDA SPECT. J. Gastroenterol. Hepatol. 2006, 21, 674-681.
22. Lazaridis KN., Gores GJ.: Primary sclerosisng cholangitis and cholangiosarcoma. Seminar in Liver
Dis. 2006, 26, 42-51.
23. Pohl J. et al.: The role of dominant stenoses in bacterial infections of bile in primera sclerosisng
cholangitis Eur. J. Gastroenterol. Hepatol. 2006, 18, 69-74.
24. Abdalian R., Heathcote EJ.: Slerosing cholangitis: a focus on secondary causes. Hepatology 2006, 44,
1063-1074.
294 Gastro Update 2007
25. Klingenberg SL, Chen W.: D-penicillamine for primary sclerosisng cholangitis. Cochrane Database
Syst. Rev. 2006, 25, CD-4182.
26. Hussaini S. et al.: Antibiotics are a major cause of drug-induced jaundice. Eur. J. Gastroeneterol.
Hepatol. 2007, 19, 15-20.
27. Giannattasio A. et al.: Steroid therapy for cases of severe drug-induced cholestasis. Ann.
Pharmacotherapy 2006, 40, 1196-1199
28. Navarro VJ., Jogh SR.: Current concenpt: drug-related hepatoxicity. N.E.J.M. 2006, 354, 731-739.
29. Ropponen A. et al.: Intrahepatic choletasis of pregnancy as idicator of liver and biliary disease: a pupulation
study. Hepatology 2006, 43, 723-728.
30. Guntupalli G., Steingrub J.: Hepatic disease and pregnancy. An overview of diagnosis and management.
J. Hepatology 2006, 35, 226-230.
31. Vallejo M. et al.: Potencial role of trans-inhibition of the bile salt export pump by progesterone metabolite int
he etiopathogenesis of intrahepatic cholestasis of pregnancy. J. Hepatology 2006, 44, 1150-1157.
33. Reyes H. et al.: Is leaky gut involved int he pathogenesis of intrahepatic cholestasis of pregnancy?
Hepatology 2006, 43, 715-722.
34. Benjaminov FS. et al.: Lived disease in pregnancy. Amer. J. Gastroenterol. 2006, 99, 2479-2488.
35. Arrese M.: Cholestasis during pregnancy: rare hepatic diseases unmasked by pregnancy. Ann Hepatol,
2006, 5, 216-218
36. Kondrackiene J., Beuers U., Kupcinkas L.: Efficacy and safety of ursodeoxycholic acid versus
cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2006, 129, 894-901.
37. Glantz A., Marschall HU., Mattson LA.: Intrahepatic cholestasis of pregnancy: a randomised controlled
trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2006, 42, 1399-1405.
38. Zapata R. et al.: Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12
year experience. Liver International 2005, 25, 548-554.
39. Altorjay I.: Emésztõszervi tünetek terhességben. Europ. J. Gastroenterol. (magyar kiadás) 2006, 10,
209-213.
40. Burrough A. et al.: Risk factors for intrahepatic cholestasis after liver transplant. Liver Transplant 2006,
12, 1626-1633.

Leave a Reply